SOUTH SAN FRANCISCO, Calif., Nov. 28 /PRNewswire-FirstCall/ -- Exelixis, Inc. (Nasdaq: EXEL) announced today that it will hold its Third Annual R&D Day on Wednesday, December 5, 2007 from 10:00 a.m. ET / 7:00 a.m. PT to 2:00 p.m. ET / 11:00 a.m. PT in New York. The company will discuss updates to its development pipeline, its collaborations, including those with GSK, BMS and Genentech, and its financial outlook for 2007.

Speakers:
-- George Scangos, PhD, President & Chief Executive Officer of Exelixis, Inc.
-- Michael Morrissey, PhD, President of Research & Development of Exelixis, Inc.
-- Frank Karbe, Executive Vice President & Chief Financial Officer of Exelixis, Inc.
-- Peter Lamb, PhD, Senior Vice President, Discovery Research & Chief Scientific Officer of Exelixis, Inc.
-- Gisela Schwab, MD, Senior Vice President and Chief Medical Officer of Exelixis, Inc.
-- Steven Sherman, MD of MD Anderson Cancer Center
-- Vince Miller, MD of Memorial Sloan-Kettering Cancer Center

The event will be webcast and may be accessed in the Event Calendar page under Investors at http://www.exelixis.com.

An archive of this webcast will be available until 9:00 p.m. PT/12:00 a.m. ET on January 4, 2008. Access numbers for this replay are: 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is: 21270665.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development for cancer and renal disease. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

SOURCE Exelixis, Inc.
/CONTACT: Investors, Charles Butler, Director, Corporate Communications, +1-650-837-7277, cbutler@exelixis.com, or Media, Soleil Maxwell Harrison, Senior Manager, Corporate Communications, +1-650-837-7012, sharrison@exelixis.com, both of Exelixis, Inc./
/Web site: http://www.exelixis.com /